Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Novartis gets FDA approval of closely watched rare disease drug
WEBDec 6, 2023 · The Food and Drug Administration has approved a new Novartis drug for adults with a rare and serious blood disorder known as paroxysmal nocturnal hemoglobinuria, or PNH. The drug, which Novartis will sell as Fabhalta, was discovered and developed by the Swiss pharmaceutical company for diseases like PNH that are driven by dysregulation of the ...
The next era of Greater Boston’s biotech boom - BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs.
Biotech of the Year: Seagen - BioPharma Dive
WEBDec 9, 2020 · Over the past year, Seagen won Food and Drug Administration approval for its second and third cancer drugs, sending its share price to record highs. Worth $33 billion, Seagen is on the cusp of joining the industry’s top ranks. “The thinking is that Seagen could emerge as the next sustainable large cap biotech company,” said Kennan MacKay ...
Biohaven starts life as new company following Pfizer buyout
WEBOct 5, 2022 · Biohaven Pharmaceutical brought a new drug to market and negotiated a multibillion-dollar buyout, both accomplishments few biotechnology companies are able to achieve. Now, the team behind that company is attempting to find similar success a second time. On Tuesday, Biohaven Ltd. officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 ...
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · Novo Nordisk's new obesity pill, based on a brain hormone, showed remarkable weight loss effects in a small trial. Read more about this breakthrough discovery.
Lilly wins FDA approval for new kind of diabetes drug - BioPharma …
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB3 days ago · BioAge Labs’ IPO was the fifth biotech stock offering priced in September and the 20th of the year, matching 2023's total.
Pharma News | BioPharma Dive
WEB3 days ago · Novo sinks on obesity drug results; Sanofi reveals anticipated MS data. A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged. By BioPharma Dive staff • Sept. 20, 2024.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · MSD is a one stop immunoassay platform with multiplexing and high throughput capabilities that allows fast, accurate and quantitative detection of biological samples at low volume. It could be a time- and cost-effective alternative to the regularly used biomolecule detection technologies in the laboratory. CONCEPT Meso Scale discovery (MSD) is an immunoassay-based platform that utilizes high ...